Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term etanercept safety in pediatric juvenile idiopathic arthritis subtypes
2010-023802-10Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etanercept in juvenile idiopathic arthritis (JIA), juvenile idiopathic arthritis, enthesitis-related (JIA-ERA) and psoriatic arthritis (PsA), sponsored by Pfizer. Primary endpoint: Occurrence of malignancy. Started Jun 2011; status: completed.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2010-023802-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023802-10.